<DOC>
	<DOCNO>NCT00012311</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . It yet know chemotherapy follow peripheral stem cell transplantation effective chemotherapy alone treat metastatic breast cancer . PURPOSE : Randomized phase II trial compare effectiveness combination chemotherapy plus peripheral stem cell transplantation chemotherapy alone treat woman stage IV breast cancer .</brief_summary>
	<brief_title>Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Chemotherapy Alone Treating Women With Stage IV Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare efficacy multi-course high-dose chemotherapy autologous peripheral blood stem cell transplantation versus standard-dose chemotherapy woman metastatic breast cancer . II . Compare five year event-free survival , term time progression time death due toxic effect , patient treat regimen . III . Compare response rate overall survival patient treat regimen . IV . Compare toxicity regimens patient population . OUTLINE : This randomize , multicenter study . Patients randomize one two treatment arm . Arm I : Patients receive docetaxel doxorubicin follow filgrastim ( G-CSF ) daily approximately 1 week . Treatment repeat approximately every 3 week 4 course . Patients receive cyclophosphamide , methotrexate , fluorouracil day 7 8 every 4 week 4 course . Arm II : Patients receive docetaxel , doxorubicin , G-CSF arm I 3 course . Patients undergo leukapheresis daily 3 4 day . Patients receive 1 course ifosfamide , etoposide , carboplatin daily 4 day blood count recover , follow 1 course cyclophosphamide thiotepa daily 4 day . Patients undergo peripheral blood stem cell reinfusion follow course . PROJECTED ACCRUAL : A total 264 patient ( 132 per arm ) accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage IV breast carcinoma Bone metastasis form metastatic disease allow No evidence bone marrow involvement aspirate biopsy No brain metastases Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 59 Sex : Female Menopausal status : Not specify Performance status : Karnofsky 80100 % Life expectancy : More 3 month Hematopoietic : Absolute neutrophil count great 1,500/mm3 Platelet count great 100,000/mm3 Hemoglobin great 9 g/dL PT normal Activated PTT normal Hepatic : Bilirubin normal ( unless benign congenital hyperbilirubinemia present ) No AST/ALT great 1.5 time upper limit normal ( ULN ) together alkaline phosphatase great 2.5 time ULN No active hepatitis B C Renal : Creatinine normal Cardiovascular : Ejection fraction normal MUGA echocardiogram No active heart disease No prior myocardial infarction manifestation coronary artery disease Other : More 1,000 calories/day oral intake HIV negative No active serious medical psychiatric disease No prior concurrent malignancy except basal cell skin cancer carcinoma situ cervix No allergy polysorbate 80 E. coliderived product No peripheral neuropathy great grade 2 Not pregnant Negative pregnancy test PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy metastatic disease No prior mitomycin , nitrosoureas , platinum coordination complex Prior adjuvant chemotherapy allow complete 6 month prior relapse metastases No 300 mg/m2 prior doxorubicin 450 mg/m2 prior epirubicin Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy brain marrowbearing pelvis Prior radiotherapy lower pelvis allow upper border radiotherapy field upper border acetabulum No prior radiotherapy pelvis Surgery : At least 2 week since prior major surgery Other : No concurrent anticancer therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>September 2001</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>